Pub. Date : 2014 Jan
PMID : 24403450
10 Functional Relationships(s)Download |
Sentence | Compound Name | Protein Name | Organism |
| 1 | UNLABELLED: BACKGROUD/AIM: We previously demonstrated that high protein expression of excision repair cross-complementation group-1 (ERCC1) was associated with poor disease-free survival in patients who received adjuvant cisplatin-based chemotherapy or chemoradiotherapy with cisplatin, and was shown to be an independent prognostic factor. | Cisplatin | ERCC excision repair 1, endonuclease non-catalytic subunit | Homo sapiens |
| 2 | UNLABELLED: BACKGROUD/AIM: We previously demonstrated that high protein expression of excision repair cross-complementation group-1 (ERCC1) was associated with poor disease-free survival in patients who received adjuvant cisplatin-based chemotherapy or chemoradiotherapy with cisplatin, and was shown to be an independent prognostic factor. | Cisplatin | ERCC excision repair 1, endonuclease non-catalytic subunit | Homo sapiens |
| 3 | UNLABELLED: BACKGROUD/AIM: We previously demonstrated that high protein expression of excision repair cross-complementation group-1 (ERCC1) was associated with poor disease-free survival in patients who received adjuvant cisplatin-based chemotherapy or chemoradiotherapy with cisplatin, and was shown to be an independent prognostic factor. | Cisplatin | ERCC excision repair 1, endonuclease non-catalytic subunit | Homo sapiens |
| 4 | UNLABELLED: BACKGROUD/AIM: We previously demonstrated that high protein expression of excision repair cross-complementation group-1 (ERCC1) was associated with poor disease-free survival in patients who received adjuvant cisplatin-based chemotherapy or chemoradiotherapy with cisplatin, and was shown to be an independent prognostic factor. | Cisplatin | ERCC excision repair 1, endonuclease non-catalytic subunit | Homo sapiens |
| 5 | In the present study, we evaluated ERCC1 expression levels in uterine cervical adenocarcinoma cell lines to assess whether they are affected by treatment with cisplatin with and without 5-fluorouracil (5-FU). | Cisplatin | ERCC excision repair 1, endonuclease non-catalytic subunit | Homo sapiens |
| 6 | ERCC1 mRNA expression levels were investigated using quantitative RT-PCR following treatment with cisplatin with and without 5-FU. | Cisplatin | ERCC excision repair 1, endonuclease non-catalytic subunit | Homo sapiens |
| 7 | ERCC1 expression was significantly elevated by cisplatin treatment, which was reduced by co-administration of 5-FU in HCA-1, TCO-2 and HCA-1R cells. | Cisplatin | ERCC excision repair 1, endonuclease non-catalytic subunit | Homo sapiens |
| 8 | CONCLUSION: The current study demonstrated an association between ERCC1 expression and sensitivity to cisplatin in cervical adenocarcinoma cells. | Cisplatin | ERCC excision repair 1, endonuclease non-catalytic subunit | Homo sapiens |
| 9 | Co-administration of cisplatin and 5-FU revealed synergistic or additive effects through inhibition of ERCC1 expression in cervical adenocarcinoma cells. | Cisplatin | ERCC excision repair 1, endonuclease non-catalytic subunit | Homo sapiens |
| 10 | Therefore, it is possible that a combination therapy of cisplatin and 5-FU or 5-FU derivatives constitutes an ideal treatment regimen, from the ERCC1 inhibition point of view in cervical adenocarcinoma. | Cisplatin | ERCC excision repair 1, endonuclease non-catalytic subunit | Homo sapiens |